James Waldron, a journalist from Fierce Biotech, brings insights on the biggest clinical trial failures of 2024. He highlights the disappointing results from major companies like AbbVie and Pfizer, particularly in trials for schizophrenia and Duchenne muscular dystrophy. The discussion delves into lessons learned from these setbacks and the human impact of failed trials. Waldron and Gabrielle Masson also explore the ongoing challenges the industry faces and the crucial need for innovative treatments to improve patient outcomes.